Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 137Parkinson Disease 4, Autosomal Dominant Lewy Body 124Melanoma 95Neoplasms 75Squamous Cell Carcinoma of Head and Neck 65Colorectal Neoplasms 42Triple Negative Breast Neoplasms 38Carcinoma, Renal Cell 37Lung Neoplasms 36Head and Neck Neoplasms 34Breast Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 32Pancreatic Neoplasms 30Ovarian Neoplasms 29Carcinoma, Transitional Cell 25Endometrial Neoplasms 19Recurrence 16Sarcoma 15Esophageal Neoplasms 15Carcinoma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Small Cell Lung Carcinoma 13Lymphoma 13Fallopian Tube Neoplasms 13Carcinoma, Squamous Cell 13Lymphoma, Non-Hodgkin 12

Interventions

Cisplatin 15Gemcitabine 7Fluorouracil 6Docetaxel 6Radiotherapy, Intensity-Modulated 5Oxaliplatin 4Capecitabine 4pembrolizumab 3Radiotherapy 3Carboplatin 3Acupuncture Therapy 3Psychiatric Rehabilitation 2Paclitaxel 2Nicotine 2Counseling 2Cetuximab 2Celecoxib 2Bupropion 2tislelizumab 1spartalizumab 1sargramostim 1motexafin gadolinium 1fosaprepitant 1fialuridine 1endostar protein 1cc-486 1apatinib 1Zoledronic Acid 1Zinc Oxide 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Nasopharyngeal Neoplasms × pembrolizumab × Clear all
NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

University of California, San Diego

Phase 2 Completed
78 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT02538510 2024-11-26

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

University of Washington

Phase 1/2 Completed
50 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms

NCT02611960 2023-07-13

Keynote-122

Merck Sharp & Dohme LLC

Phase 3 Completed
233 enrolled 21 charts
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡